Rolling Meadows, ILLINOIS3 Active Studies

Atopic Dermatitis Clinical Trials in Rolling Meadows, ILLINOIS

Find 3 actively recruiting atopic dermatitis clinical trials in Rolling Meadows, ILLINOIS. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
475
Enrolling

Recruiting Atopic Dermatitis Studies in Rolling Meadows

About Atopic Dermatitis Clinical Trials in Rolling Meadows

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 3 atopic dermatitis clinical trials recruiting participants in Rolling Meadows, ILLINOIS. These studies are seeking a combined 475 participants. Research is being sponsored by Inmagene LLC, Lantern Pharma Inc., AbbVie. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Rolling Meadows — FAQ

Are there atopic dermatitis clinical trials in Rolling Meadows?

Yes, there are 3 atopic dermatitis clinical trials currently recruiting in Rolling Meadows, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rolling Meadows?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rolling Meadows research site will contact you about next steps.

Are clinical trials in Rolling Meadows free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rolling Meadows studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 3 active trials in Rolling Meadows are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated March 2, 2026 from ClinicalTrials.gov